Portfolio of premium, high-growth botanic beverages and self care products
Post-money valuation โ
$100.0M
As of Jan 2025 ยท from Reg CF Offering (2024) ยท pre-money + amount raised, not a traded price
Total raised
$2,245,119
Across 5 rounds since 2021
Latest share price
$2.82
Reg CF Offering (2026) offering price
Financials
FY2018โFY2024 ยท from SEC filings ยท hover any figure for its source
$535K
โ$2.4M
2018
$3.5M
โ$3.3M
2019
$3.4M
โ$3.3M
2020
$3.5M
โ$3.4M
2021
$3.1M
โ$5.6M
2022
$33.5M
$4.9M
2023
$21.7M
โ$10.7M
2024
RevenueNet income โ beside revenue when positive, below the line when a loss
Metric
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Income statement
Revenue
$534,617
$3,469,715
$3,422,725
$3,493,085
$3,074,322
$33,483,852
$21,668,525
Cost of goods sold
$291,410
$2,092,017
$2,125,571
$2,589,340
$1,766,962
$22,734,166
$16,661,809
Gross margin
45%
40%
38%
26%
43%
32%
23%
Net income
-$2,427,676
-$3,344,912
-$3,347,973
-$3,377,998
-$5,590,679
$4,923,301
-$10,667,562
Taxes paid
$0
$0
$0
$0
$0
$0
$38,706
Balance sheet
Cash
$253,728
$836,524
$835,762
$842,624
$1,583,679
$939,975
$693,946
Accounts receivable
$102,982
$535,049
$481,908
$811,183
$423,285
$3,782,276
$3,341,357
Total assets
$955,680
$2,819,172
$2,793,112
$8,640,758
$14,177,044
$37,634,295
$40,521,736
Short-term debt
$132,159
$597,928
$4,975,875
$126,897
$1,000,000
$11,123,996
$19,692,906
Long-term debt
$4,124,992
$8,431,902
$4,578,396
$1,805,362
$4,964,392
$87,740,105
$1,814,570
Total liabilities
$4,257,151
$9,029,830
$9,554,271
$1,932,259
$5,964,392
$98,864,101
$21,507,476
Other
Headcount
โ
31
โ
34
42
38
26
Figures as reported by the issuer in the filing shown on hover. Each yearโs pill shows the assurance level of its filed statements โ audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didnโt state one. Headcount is the filingโs point-in-time count, not a year-end average. Manually corrected figures are marked โCorrectedโ.
A dashed amber step is a SAFE/note valuation cap โ a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
About this data. Figures are compiled from public sources โ SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages โ and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.